Trials / Completed
CompletedNCT00485823
Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia
The Assessment of a Weight Management Program for Treatment-Emergent Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, and Schizoaffective Disorder During Olanzapine Therapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to develop the weight management program, which is combined with healthy diet, proper physical exercise, and behavior modification, related to patient's quality of life. The patients groups are in routine practice with 5-20 mg olanzapine. The study results may be utilized for patients who have gained weight on olanzapine and also other antipsychotic drugs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olanzapine Hydrochloride | |
| PROCEDURE | Weight Management Program |
Timeline
- Start date
- 2002-12-01
- Completion
- 2003-09-01
- First posted
- 2007-06-13
- Last updated
- 2007-06-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00485823. Inclusion in this directory is not an endorsement.